Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice

Objective: Pharmacological strategies that engage multiple mechanisms-of-action have demonstrated synergistic benefits for metabolic disease in preclinical models. One approach, concurrent activation of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon...

Full description

Bibliographic Details

Published in:	Molecular Metabolism
Main Authors:	Patrick J. Knerr, Stephanie A. Mowery, Jonathan D. Douros, Bhavesh Premdjee, Karina Rahr Hjøllund, Yantao He, Ann Maria Kruse Hansen, Anette K. Olsen, Diego Perez-Tilve, Richard D. DiMarchi, Brian Finan
Format:	Article
Language:	English
Published:	Elsevier 2022-09-01
Subjects:	Obesity Pharmacology Triagonist Glucagon GLP-1 GIP
Online Access:	http://www.sciencedirect.com/science/article/pii/S2212877822001028